Recombinant immunotoxin

Recombinant immunotoxin technology is at the forefront of targeted cancer therapy, offering a promising approach to selectively destroy cancer cells while sparing healthy tissue. A recombinant immunotoxin is engineered by fusing a portion of an antibody, which specifically targets cancer cell antigens, with a potent toxin capable of inducing cell death. This targeted approach enhances the precision and effectiveness of cancer treatments, minimizing adverse side effects associated with traditional therapies. As research advances, recombinant immunotoxins are poised to play a crucial role in developing more efficient cancer treatments, providing new hope for patients battling various malignancies.